BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 28586051)

  • 21. Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma.
    Wang X; Han L; Zhang J; Xia Q
    Dig Dis Sci; 2015 Oct; 60(10):3011-8. PubMed ID: 26055238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].
    Longerich T
    Pathologe; 2014 Nov; 35 Suppl 2():177-84. PubMed ID: 25394965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma.
    Rahmani F; Ziaeemehr A; Shahidsales S; Gharib M; Khazaei M; Ferns GA; Ryzhikov M; Avan A; Hassanian SM
    J Cell Physiol; 2020 May; 235(5):4146-4152. PubMed ID: 31663122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
    Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
    Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.
    Zhangyuan G; Wang F; Zhang H; Jiang R; Tao X; Yu D; Jin K; Yu W; Liu Y; Yin Y; Shen J; Xu Q; Zhang W; Sun B
    Oncogene; 2020 Feb; 39(6):1213-1230. PubMed ID: 31605014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long noncoding RNA HAGLROS promotes cell proliferation, inhibits apoptosis and enhances autophagy via regulating miR-5095/ATG12 axis in hepatocellular carcinoma cells.
    Wei H; Hu J; Pu J; Tang Q; Li W; Ma R; Xu Z; Tan C; Yao T; Wu X; Long X; Wang J
    Int Immunopharmacol; 2019 Aug; 73():72-80. PubMed ID: 31082725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-34a and miR-125a-5p inhibit proliferation and metastasis but induce apoptosis in hepatocellular carcinoma cells via repressing the MACC1-mediated PI3K/AKT/mTOR pathway.
    Zhang YM; Wu QM; Chang LY; Liu JC
    Neoplasma; 2020 Sep; 67(5):1042-1053. PubMed ID: 32484698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
    Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
    Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.
    Ma YS; Wu TM; Qian B; Liu YS; Ding H; Fan MM; Liu JB; Yu F; Wang HM; Shi Y; Gu LP; Li L; Tian LL; Wang PY; Wang GR; Wu ZJ; Zou QF; Ling CC; Fu D
    J Cell Mol Med; 2021 Apr; 25(8):4040-4052. PubMed ID: 33621431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-3127 promotes cell proliferation and tumorigenicity in hepatocellular carcinoma by disrupting of PI3K/AKT negative regulation.
    Jiang J; Zhang Y; Guo Y; Yu C; Chen M; Li Z; Tian S; Sun C
    Oncotarget; 2015 Mar; 6(8):6359-72. PubMed ID: 25849943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway.
    Jin J; Guo Y; Liu Y; Wang Z; Yang X; Sun S
    Oncol Rep; 2019 Sep; 42(3):1183-1193. PubMed ID: 31233204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-37 induces autophagy in hepatocellular carcinoma cells by inhibiting the PI3K/AKT/mTOR pathway.
    Li TT; Zhu D; Mou T; Guo Z; Pu JL; Chen QS; Wei XF; Wu ZJ
    Mol Immunol; 2017 Jul; 87():132-140. PubMed ID: 28433890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
    Wu XL; Wang LK; Yang DD; Qu M; Yang YJ; Guo F; Han L; Xue J
    J Cell Biochem; 2018 Feb; 119(2):2356-2367. PubMed ID: 28884839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway.
    Yin F; Huang X; Xuan Y
    Dis Markers; 2021; 2021():9950663. PubMed ID: 34512817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/AKT pathway by targeting EGFR.
    Ma HP; Kong WX; Li XY; Li W; Zhang Y; Wu Y
    Oncol Rep; 2019 Mar; 41(3):1549-1559. PubMed ID: 30747217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma.
    Yu M; Xue H; Wang Y; Shen Q; Jiang Q; Zhang X; Li K; Jia M; Jia J; Xu J; Tian Y
    Int J Oncol; 2017 Mar; 50(3):975-983. PubMed ID: 28098858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
    Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
    Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
    [No Abstract]   [Full Text] [Related]  

  • 38. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
    Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
    Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of GRIM-19, a mitochondrial respiratory chain complex I protein, suppresses hepatocellular carcinoma growth.
    Kong D; Zhao L; Du Y; He P; Zou Y; Yang L; Sun L; Wang H; Xu D; Meng X; Sun X
    Int J Clin Exp Pathol; 2014; 7(11):7497-507. PubMed ID: 25550785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
    Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
    Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.